Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Hepatocellular Carcinoma | Research

Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK/eIF2α/ATF4/CHOP axis in hepatocellular carcinoma

Authors: Sanghwa Kim, Minji Lee, Yeonhwa Song, Su-Yeon Lee, Inhee Choi, I-Seul Park, Jiho Kim, Jin-sun Kim, Kang mo Kim, Haeng Ran Seo

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most common malignant cancers worldwide, and liver cancer has increased in mortality due to liver cancer because it was detected at an advanced stages in patients with liver dysfunction, making HCC a lethal cancer. Accordingly, we aim to new targets for HCC drug discovery using HCC tumor spheroids.

Methods

Our comparative proteomic analysis of HCC cells grown in culture as monolayers (2D) and spheroids (3D) revealed that argininosuccinate synthase 1 (ASS1) expression was higher in 3D cells than in 2D cells due to upregulated endoplasmic reticulum (ER) stress responses. We investigated the clinical value of ASS1 in Korean patients with HCC. The mechanism underlying ASS1-mediated tumor suppression was investigated in HCC spheroids. ASS1-mediated improvement of chemotherapy efficiency was observed using high content screening in an HCC xenograft mouse model.

Results

Studies of tumor tissue from Korean HCC patients showed that, although ASS1 expression was low in most samples, high levels of ASS1 were associated with favorable overall survival of patients. Here, we found that bidirectional interactions between ASS1 ER stress responses in HCC-derived multicellular tumor spheroids can limit HCC progression. ASS1 overexpression effectively inhibited tumor growth and enhanced the efficacy of in vitro and in vivo anti-HCC combination chemotherapy via activation of the PERK/eIF2α/ATF4/CHOP axis, but was not dependent on the status of p53 and arginine metabolism.

Conclusions

These results demonstrate the critical functional roles for the arginine metabolism–independent tumor suppressor activity of ASS1 in HCC and suggest that upregulating ASS1 in these tumors is a potential strategy in HCC cells with low ASS1 expression.

Available only for authorised users

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. https://doi.org/10.1016/S1470-2045(08)70285-7.CrossRefPubMed

Tsun ZY, Possemato R. Amino acid management in cancer. Semin Cell Dev Biol. 2015;43:22–32. https://doi.org/10.1016/j.semcdb.2015.08.002.CrossRefPubMedPubMedCentral

Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014;39(4):191–8. https://doi.org/10.1016/j.tibs.2014.02.004.CrossRefPubMedPubMedCentral

Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427–33. https://doi.org/10.1016/j.tibs.2010.05.003.CrossRefPubMedPubMedCentral

Lind DS. Arginine and cancer. J Nutr. 2004;134(10 Suppl):2837S–41S discussion 2853S.CrossRef

Jobgen WS, Fried SK, Fu WJ, Meininger CJ, Wu G. Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem. 2006;17(9):571–88. https://doi.org/10.1016/j.jnutbio.2005.12.001.CrossRefPubMed

Leuzzi V, Alessandri MG, Casarano M, Battini R, Cioni G. Arginine and glycine stimulate creatine synthesis in creatine transporter 1-deficient lymphoblasts. Anal Biochem. 2008;375(1):153–5. https://doi.org/10.1016/j.ab.2008.01.018.CrossRefPubMed

Song Y, Kim JS, Kim SH, Park YK, Yu E, Kim KH, Seo EJ, Oh HB, Lee HC, Kim KM, Seo HR. Patient-derived multicellular tumor spheroids towards optimized treatment for patients with hepatocellular carcinoma. J Exp Clin Cancer Res. 2018;37(1):109. https://doi.org/10.1186/s13046-018-0752-0.CrossRefPubMedPubMedCentral

Song Y, Lee SY, Kim S, Choi I, Kim SH, Shum D, Heo J, Kim AR, Kim KM, Seo HR. Inhibitors of Na(+)/K(+) ATPase exhibit antitumor effects on multicellular tumor spheroids of hepatocellular carcinoma. Sci Rep. 2020;10(1):5318. https://doi.org/10.1038/s41598-020-62134-4.CrossRefPubMedPubMedCentral

10.

Jia Z, Cheng Y, Jiang X, Zhang C, Wang G, Xu J, Li Y, Peng Q, Gao Y. 3D culture system for liver tissue mimicking hepatic plates for improvement of human hepatocyte (C3A) function and polarity. Biomed Res Int. 2020;2020:6354183.PubMedPubMedCentral

11.

Lauschke VM, Shafagh RZ, Hendriks DFG, Ingelman-Sundberg M. 3D primary hepatocyte culture Systems for Analyses of liver diseases, drug metabolism, and toxicity: emerging culture paradigms and applications. Biotechnol J. 2019;14(7):e1800347. https://doi.org/10.1002/biot.201800347.CrossRefPubMed

12.

Wu L, Li L, Meng S, Qi R, Mao Z, Lin M. Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28(2):365–8. https://doi.org/10.1111/jgh.12043.CrossRefPubMed

13.

Tsai CY, Chi HC, Chi LM, Yang HY, Tsai MM, Lee KF, Huang HW, Chou LF, Cheng AJ, Yang CW, Wang CS, Lin KH. Argininosuccinate synthetase 1 contributes to gastric cancer invasion and progression by modulating autophagy. FASEB J. 2018;32(5):2601–14. https://doi.org/10.1096/fj.201700094r.CrossRefPubMed

14.

Long Y, Tsai WB, Chang JT, Estecio M, Wangpaichitr M, Savaraj N, Feun LG, Chen HH, Kuo MT. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1alpha, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation. Oncotarget. 2016;7(50):82658–70. https://doi.org/10.18632/oncotarget.12308.CrossRefPubMedPubMedCentral

15.

Rozpedek W, Pytel D, Mucha B, Leszczynska H, Diehl JA, Majsterek I. The role of the PERK/eIF2alpha/ATF4/CHOP signaling pathway in tumor progression during endoplasmic reticulum stress. Curr Mol Med. 2016;16(6):533–44. https://doi.org/10.2174/1566524016666160523143937.CrossRefPubMedPubMedCentral

16.

Sicari D, Fantuz M, Bellazzo A, Valentino E, Apollonio M, Pontisso I, Di Cristino F, Dal Ferro M, Bicciato S, Del Sal G, et al. Mutant p53 improves cancer cells' resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6. Oncogene. 2019;38(34):6184–95. https://doi.org/10.1038/s41388-019-0878-3.CrossRefPubMed

17.

Cubillos-Ruiz JR, Bettigole SE, Glimcher LH. Molecular pathways: immunosuppressive roles of IRE1alpha-XBP1 signaling in dendritic cells of the tumor microenvironment. Clin Cancer Res. 2016;22(9):2121–6. https://doi.org/10.1158/1078-0432.CCR-15-1570.CrossRefPubMedPubMedCentral

18.

Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012;13(2):89–102. https://doi.org/10.1038/nrm3270.CrossRefPubMed

19.

Pino SC, O'Sullivan-Murphy B, Lidstone EA, Yang C, Lipson KL, Jurczyk A, di Iorio P, Brehm MA, Mordes JP, Greiner DL, et al. CHOP mediates endoplasmic reticulum stress-induced apoptosis in Gimap5-deficient T cells. PLoS One. 2009;4(5):e5468. https://doi.org/10.1371/journal.pone.0005468.CrossRefPubMedPubMedCentral

20.

Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang Y, Jungreis R, Nagata K, Harding HP, Ron D. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev. 2004;18(24):3066–77. https://doi.org/10.1101/gad.1250704.CrossRefPubMedPubMedCentral

21.

Liu L, Qin S, Zheng Y, Han L, Zhang M, Luo N, Liu Z, Gu N, Gu X, Yin X. Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. Cancer Biol Ther. 2017;18(3):166–76. https://doi.org/10.1080/15384047.2017.1282019.CrossRefPubMedPubMedCentral

22.

Cao G, Li X, Qin C, Li J. Prognostic value of VEGF in hepatocellular carcinoma patients treated with Sorafenib: a meta-analysis. Med Sci Monit. 2015;21:3144–51. https://doi.org/10.12659/MSM.894617.CrossRefPubMedPubMedCentral

23.

Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther. 2009;9(4):503–9. https://doi.org/10.1586/era.09.6.CrossRefPubMed

24.

Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8(5):292–301. https://doi.org/10.1038/nrclinonc.2011.30.CrossRefPubMedPubMedCentral

25.

Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129–40. https://doi.org/10.1158/1535-7163.MCT-08-0013.CrossRefPubMed

26.

Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835–44. https://doi.org/10.1038/nrd2130.CrossRefPubMed

27.

Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38(5):614–22. https://doi.org/10.1038/aps.2017.5.CrossRefPubMedPubMedCentral

28.

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73. https://doi.org/10.1016/S0140-6736(18)30207-1.CrossRefPubMed

29.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.CrossRefPubMed

30.

Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M, REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–70. https://doi.org/10.1016/S1470-2045(15)00050-9.CrossRefPubMed

31.

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. https://doi.org/10.1056/NEJMoa1717002.CrossRefPubMedPubMedCentral

32.

Greten TF, Sangro B. Targets for immunotherapy of liver cancer. J Hepatol. 2018;68(1):P157–66.

33.

Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: current and future. World J Gastroenterol. 2019;25(24):2977–89. https://doi.org/10.3748/wjg.v25.i24.2977.CrossRefPubMedPubMedCentral

34.

Raybould AL, Sanoff H. Combination Antiangiogenic and immunotherapy for advanced hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma. 2020;7:133–42. https://doi.org/10.2147/JHC.S224938.CrossRefPubMedPubMedCentral

35.

Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–24. https://doi.org/10.1093/intimm/dxm057.CrossRef

36.

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THR, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502. https://doi.org/10.1016/S0140-6736(17)31046-2.CrossRefPubMedPubMedCentral

37.

Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192(2):303–10. https://doi.org/10.1084/jem.192.2.303.CrossRefPubMedPubMedCentral

38.

Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37(1):110. https://doi.org/10.1186/s13046-018-0777-4.CrossRefPubMedPubMedCentral

39.

Bouattour M, Raymond E, Qin S, Cheng AL, Stammberger U, Locatelli G, Faivre S. Recent developments of c-met as a therapeutic target in hepatocellular carcinoma. Hepatology. 2018;67(3):1132–49. https://doi.org/10.1002/hep.29496.CrossRefPubMedPubMedCentral

40.

Giannelli G, Villa E, Lahn M. Transforming growth factor-beta as a therapeutic target in hepatocellular carcinoma. Cancer Res. 2014;74(7):1890–4. https://doi.org/10.1158/0008-5472.CAN-14-0243.CrossRefPubMed

41.

Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J, Zhang LJ. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res. 2009;39(2):177–86. https://doi.org/10.1111/j.1872-034X.2008.00449.x.CrossRefPubMed

42.

Della Corte CM, Viscardi G, Papaccio F, Esposito G, Martini G, Ciardiello D, Martinelli E, Ciardiello F, Morgillo F. Implication of the hedgehog pathway in hepatocellular carcinoma. World J Gastroenterol. 2017;23(24):4330–40. https://doi.org/10.3748/wjg.v23.i24.4330.CrossRefPubMedPubMedCentral

43.

Gouirand V, Guillaumond F, Vasseur S. Influence of the tumor microenvironment on Cancer cells metabolic reprogramming. Front Oncol. 2018;8:117. https://doi.org/10.3389/fonc.2018.00117.CrossRefPubMedPubMedCentral

44.

Yang LV. Tumor Microenvironment and Metabolism. Int J Mol Sci. 2017;18(12):2729.

45.

Barbone D, Van Dam L, Follo C, Jithesh PV, Zhang SD, Richards WG, Bueno R, Fennell DA, Broaddus VC. Analysis of gene expression in 3D spheroids highlights a survival role for ASS1 in mesothelioma. PLoS One. 2016;11(3):e0150044. https://doi.org/10.1371/journal.pone.0150044.CrossRefPubMedPubMedCentral

46.

Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010;126(12):2762–72.PubMed

47.

Barbul A. Arginine: biochemistry, physiology, and therapeutic implications. JPEN J Parenter Enteral Nutr. 1986;10(2):227–38. https://doi.org/10.1177/0148607186010002227.CrossRefPubMed

48.

Cheng PN, Leung YC, Lo WH, Tsui SM, Lam KC. Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma. Cancer Lett. 2005;224(1):67–80. https://doi.org/10.1016/j.canlet.2004.10.050.CrossRefPubMed

49.

Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A, Mitchell TJ, Whittaker SJ, et al. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis. 2012;3(7):e342. https://doi.org/10.1038/cddis.2012.83.CrossRefPubMedPubMedCentral

50.

Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer. 2004;100(4):826–33. https://doi.org/10.1002/cncr.20057.CrossRefPubMed

51.

Huang HY, Wu WR, Wang YH, Wang JW, Fang FM, Tsai JW, Li SH, Hung HC, Yu SC, Lan J, Shiue YL, Hsing CH, Chen LT, Li CF. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res. 2013;19(11):2861–72. https://doi.org/10.1158/1078-0432.CCR-12-2641.CrossRefPubMed

52.

Miyamoto T, Lo PHY, Saichi N, Ueda K, Hirata M, Tanikawa C, Matsuda K. Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53. Sci Adv. 2017;3(5):e1603204. https://doi.org/10.1126/sciadv.1603204.CrossRefPubMedPubMedCentral

53.

Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M, Honda K, Yamaguchi U, Shoji A, Tochigi N, Morioka H, Toyama Y, Hirohashi S, Kawai A, Yamada T. Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther. 2010;9(3):535–44. https://doi.org/10.1158/1535-7163.MCT-09-0774.CrossRefPubMed

54.

Shan YS, Hsu HP, Lai MD, Yen MC, Chen WC, Fang JH, Weng TY, Chen YL. Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines. Sci Rep. 2015;5(1):9783. https://doi.org/10.1038/srep09783.CrossRefPubMedPubMedCentral

55.

Szlosarek PW, Grimshaw MJ, Wilbanks GD, Hagemann T, Wilson JL, Burke F, Stamp G, Balkwill FR. Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer. Int J Cancer. 2007;121(1):6–11. https://doi.org/10.1002/ijc.22666.CrossRefPubMed

56.

Bobak Y, Kurlishchuk Y, Vynnytska-Myronovska B, Grydzuk O, Shuvayeva G, Redowicz MJ, Kunz-Schughart LA, Stasyk O. Arginine deprivation induces endoplasmic reticulum stress in human solid cancer cells. Int J Biochem Cell Biol. 2016;70:29–38. https://doi.org/10.1016/j.biocel.2015.10.027.CrossRefPubMed

57.

Mun GI, Kim IS, Lee BH, Boo YC. Endothelial argininosuccinate synthetase 1 regulates nitric oxide production and monocyte adhesion under static and laminar shear stress conditions. J Biol Chem. 2011;286(4):2536–42. https://doi.org/10.1074/jbc.M110.180489.CrossRefPubMed

58.

Mun GI, Boo YC. A regulatory role of Kruppel-like factor 4 in endothelial argininosuccinate synthetase 1 expression in response to laminar shear stress. Biochem Biophys Res Commun. 2012;420(2):450–5. https://doi.org/10.1016/j.bbrc.2012.03.016.CrossRefPubMed

Title: Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK/eIF2α/ATF4/CHOP axis in hepatocellular carcinoma
Authors: Sanghwa Kim
Minji Lee
Yeonhwa Song
Su-Yeon Lee
Inhee Choi
I-Seul Park
Jiho Kim
Jin-sun Kim
Kang mo Kim
Haeng Ran Seo
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-01912-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Overexpression of NELFE contributes to gastric cancer progression via Wnt/β-catenin signaling-mediated activation of CSNK2B expression

Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer

Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis

A specific tRNA half, 5’tiRNA-His-GTG, responds to hypoxia via the HIF1α/ANG axis and promotes colorectal cancer progression by regulating LATS2

Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer

Empty spiracles homeobox genes EMX1 and EMX2 regulate WNT pathway activation in sarcomagenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer